Aquatic Capital Management LLC Invests $1.08 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Aquatic Capital Management LLC acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,901 shares of the company’s stock, valued at approximately $1,081,000.

Several other large investors also recently bought and sold shares of KRYS. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter valued at approximately $40,000. Covestor Ltd lifted its holdings in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the period. Avanza Fonder AB bought a new stake in shares of Krystal Biotech during the 4th quarter valued at about $119,000. KBC Group NV increased its position in shares of Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research reports. HC Wainwright upped their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a “buy” rating in a report on Monday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and an average target price of $222.71.

Krystal Biotech Trading Down 0.4 %

NASDAQ:KRYS opened at $169.88 on Thursday. The stock has a 50-day moving average price of $175.64 and a 200 day moving average price of $171.48. The stock has a market capitalization of $4.91 billion, a P/E ratio of 56.82 and a beta of 0.75. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period last year, the firm posted $0.30 EPS. The company’s revenue was up 116.4% on a year-over-year basis. On average, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).